Corbus Pharmaceuticals (NASDAQ:CRBP) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Corbus Pharmaceuticals (NASDAQ:CRBP – Get Rating) in a research report issued to clients and investors on Wednesday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock. Separately, Zacks Investment Research upgraded shares of Corbus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.50 […]

Related Keywords

,Jpmorgan Chase Co ,Corbus Pharmaceuticals Company Profile Get Rating ,Zacks Investment Research ,Corbus Pharmaceuticals ,Corbus Pharmaceuticals Holdings Inc ,Parametric Portfolio Associates ,Get Rating ,Wealth Management ,Portfolio Associates ,Sigma Investments ,Aries Wealth Management ,Pharmaceuticals Company Profile ,Pharmaceuticals Holdings ,Nasdaq Crbp ,Crbp ,Medical ,Initiated Coverage ,Stocknews Com ,